Atea Announces Update of Clinical Studies Evaluating AT-527 for COVID-19 in the Outpatient Setting

Name of listed company: Chugai Pharmaceutical Co., Ltd. Code number: 4519 (1 st Section of Tokyo Stock Exchange) Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo President & CEO: Osamu Okuda Inquiries to: Toshiya Sasai Head of Corporate Communications Dept. Tel:+81-(0)3-3273-0554 Chugai Pharmaceutical Co., Ltd. announced that Atea issued a press release on November 11 regarding update of MOONSONG study and MORNINGSKY study evaluating the RNA polymerase inhibitor AT-527 for COVID-19 in the outpatient setting. Please refer to the link below for details of the press release: Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-clinical-and-corporate-update-0

The release as fetched from its publisher. chugai-pharm.co.jp ↗